Sponsor study identifier
interventional
14
0 countries
N/A
Study Start
March 2006
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
April 2006
Actual (reported)Study Completion
April 2006
Actual (reported)Previous epidemiological studies have shown that in cardiovascular patients, the 34C\>T variant in the gene encoding for the enzyme Adenosine Mono Phosphate Deaminase (AMPD1) is associated with prolonged survival. The 34 C\>T variant encodes a severely truncated, metabolically inactive protein. We hypothesize that during ischemia, in these patients AMP in preferentially converted into adenosine instead of IMP. Adenosine receptor stimulation, in turn, will increase resistance to ischemia-reperfusion in the myocardial tissue. To test this hypothesis, 7 male healthy volunteers heterozygous for the 34C\>T variant will be selected from 100 healthy volunteers, which we have previously genotyped. These subjects will be compared with 7 matched control subjects. Individual ischemic tolerance will be assessed in the thenar muscle using 99mTc-Annexin A5 scintigraphy. Briefly, the circulation of the nondominant forearm will be interrupted for 10 minutes by inflation of an upperarm cuff to 200mmHg en concomitantly, the subjects will perform isometric rhythmic handgripping until exhaustion. Immediately upon reperfusion, 400 MBq of 99mTc-Annexin A5 will be administered intravenously. Finally, 1 and 4 hours post-injection, scintigrapghi imaging of both hand will be performed. Targeting of annexin A5 will be expressed as percentage difference between the experimental and control hand.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 2006
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 2006
Date type not reportedThis date has not been verified as actual or estimated.
April 2006
Actual (reported)April 2006
Actual (reported)April 27, 2006
Actual (reported)April 27, 2006
Actual (reported)99mTc-Annexin A5 targeting
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Gerard Rongen, MD, PhD
Radboud University Medical Center
First Submitted
April 27, 2006
First Posted
April 27, 2006
Study Start
March 2006
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
April 2006
Actual (reported)Contact the study team to confirm eligibility.
Study Completion
April 2006
Actual (reported)Last Updated
April 22, 2016
Record last verified: 2016-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: